Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
ST8155AA1 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) with a mechanism targeting histone deacetylases (HDACs). This compound exhibits significant antitumor activity, making it a valuable tool for cancer research, particularly in the development of targeted therapies. Its application in ADCs enhances the specificity and efficacy of therapeutic agents against tumor cells. -
Drug-Linker Conjugates for ADC
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a peptide-cleavable drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The maytansinoid moiety (DM) enhances cytotoxicity, making this conjugate an effective tool for targeted cancer therapy. Its unique chemical structure allows for precise release of the therapeutic agent in the tumor microenvironment, facilitating specific delivery and reduced systemic toxicity. This reagent is suitable for research focusing on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Mal-VC-PAB-ABAEP-Azonafide is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent cytotoxic effects of Azonafide with the Mal-VC-PAB linker to enhance targeted delivery and efficacy against tumor cells. This reagent is utilized in research focusing on advanced therapeutic strategies for cancer treatment, specifically in the development of ADCs that aim to improve therapeutic selectivity while minimizing systemic toxicity. -
Drug-Linker Conjugate For ADC
Val-Cit-PAB-MMAF is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound integrates a peptide linker, Val-Cit-PAB, with MMAF, a highly effective inhibitor of tubulin polymerization. Val-Cit-PAB-MMAF is utilized in research focusing on targeted cancer therapies, enhancing the specificity and efficacy of ADCs through selective delivery mechanisms. -
Drug-Linker Conjugates for ADC
Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan serves as a potent drug-linker conjugate for antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while reducing off-target effects. It is particularly valuable in the development of innovative cancer treatments, enabling precise targeting and improved pharmacokinetic profiles. -
Drug-Linker Conjugate for ADC
TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a topoisomerase 1 inhibitor and a cleavable linker, facilitating controlled release of the active drug upon target interaction. It is suitable for the synthesis of ADCs aimed at enhancing the specificity and efficacy of therapeutic agents in cancer research and treatment. -
Drug-linker Conjugate For ADC
MC-Gly-Gly-Phe-Exatecan analog 38 is a linker compound designed for use in antibody-drug conjugates (ADCs). This synthetic analog facilitates the delivery of cytotoxic agents to targeted cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It serves as a valuable tool in cancer research for the development and synthesis of various ADCs. -
Drug-Linker Conjugates for ADC
GDP-Fuc-AM-VcPAB-MMAE is a conjugate of the cytotoxic agent Monomethyl auristatin E (MMAE) linked via a specific linker system. This precursor molecule plays a critical role in the development of antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutics in cancer research. Its utilization in experimental studies aids in the exploration of ADC efficacy and potential treatment pathways for neoplastic diseases. -
Drug-Linker Conjugate for ADC
Ledadotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises Auristatin F-hydroxypropylamide, a microtubule inhibitor, linked to a specialized PEG-based linker. This compound is utilized in the synthesis of the ADC Emiltatug ledadotin, making it valuable for targeted cancer therapies and related research applications. -
Drug-Linker Conjugates for ADC
DM21-L-G is a drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to targeted cells, enhancing therapeutic efficacy while minimizing off-target effects. Its application is critical in the development of targeted cancer therapies, enabling researchers to explore new avenues in precision medicine. -
Drug-Linker Conjugates for ADC
Amidate-VC-PAB-MMAF is a cleavable drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines the Amidate-VC-PAB linker with MMAF, a potent inhibitor of tubulin polymerization, to enhance the targeted delivery of therapeutic agents. By utilizing this linker, researchers can minimize off-target cytotoxicity while improving the efficacy of ADCs in cancer treatments and other applications in drug development. -
Drug-Linker Conjugates for ADC
PNU-EDA-Gly5 is an oligo-glycine linker designed for antibody-drug conjugate (ADC) synthesis, consisting of the DNA topoisomerase I inhibitor PNU-159682 linked to EDA-Gly5. This compound facilitates targeted delivery of cytotoxic agents while maintaining the activity of the payload, making it useful for the development of ADCs aimed at cancer therapies. Researchers can utilize PNU-EDA-Gly5 to explore novel therapeutic strategies in oncology and enhance the efficacy of targeted treatment modalities. -
Drug-Linker Conjugate for ADC
APL-1092 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent payload Exatecan. The structure incorporates a stable linker to facilitate precise delivery of the cytotoxic agent to targeted cells. APL-1092 is intended for research into targeted cancer therapies, offering a promising tool for studying the efficacy and mechanism of ADCs in various tumor models. -
Drug-Linker Conjugates for ADC
MB-VC-MGBA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a potent antitumor activity mechanism. This compound employs MGBA, a minor-groove-binding DNA-alkylating agent, connected through the linker MB-VC, providing effective targeted delivery in cancer therapy research. Its unique design facilitates precise targeting and enhances therapeutic efficacy for various malignancies. -
Drug-Linker Conjugates for ADC
Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a unique ADC linker (Mc-Lys(PEG12)-Cap-Ala-Ala-PABC) combined with the potent DNA topoisomerase I inhibitor, Exatecan. It is particularly relevant for the development of targeted therapies against HER2-positive breast cancer, facilitating the selective delivery of cytotoxic agents to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
XB010 drug-linker is a conjugate that combines MMAE with RED-601, specifically designed for the synthesis of antibody-drug conjugates (ADCs). This drug-linker facilitates targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Researchers utilize XB010 for the development of ADCs aimed at improving anticancer treatments and studying the mechanisms of drug action in tumor biology. -
Drug-Linker Conjugates for ADC
DBA-DM4 is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent tubulin inhibitor DM1 with the SPDP linker to facilitate targeted delivery of cytotoxic agents to cancer cells. DBA-DM4 is utilized in research aimed at enhancing the efficacy and selectivity of therapeutic antibodies in oncology, making it a valuable tool for the development of novel cancer treatments. -
Drug-Linker Conjugate for ADC
Mal-PEG8-Phe-Lys-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a degradable linker composed of Mal-PEG8-Phe-Lys-PAB, covalently linked to the potent cytotoxic agent Exatecan. It is utilized in research focusing on targeted cancer therapies, enabling the effective delivery of cytotoxic agents to cancer cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
N-(Hexanoyloxy)succinimide-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a hexanoyloxy group and a degradable PEG linker, which facilitates the delivery of the cytotoxic agent MMAE to target cells. This compound shows significant antitumor activity and is useful in the development of targeted cancer therapies, enhancing the efficacy of ADCs by minimizing off-target effects. -
Drug-linker Conjugate for ADC
Rha-PEG3-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. Featuring a noncleavable linker, Rha-PEG3 enhances the stability and efficacy of the conjugate while the SMCC protein crosslinker facilitates the attachment to monoclonal antibodies. This compound exhibits potent antitumor activity, making it suitable for cancer research and the development of targeted therapies. -
Drug-Linker Conjugates for ADC
Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the payload MMAE and the linker Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB, enabling effective targeted delivery of cytotoxic agents to cancer cells. The conjugate functions by utilizing the specificity of antibodies to selectively deliver the cytotoxic MMAE, facilitating enhanced therapeutic efficacy in oncological research. -
Drug-Linker Conjugate for ADC
STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound functions by targeting the STING pathway, enhancing immune responses against tumors. It is ideal for ADC synthesis, featuring a target protein ligand, E3 ligase ligand, and a flexible linker structure, facilitating efficient delivery of cytotoxic agents to cancer cells. -
Drug-Linker Conjugates for ADC
Deruxtecan analog 2 monoTFA is a derivative of Deruxtecan and serves as a drug-linker conjugate for antibody-drug conjugates (ADCs). This compound features the DX-8951 derivative (Dxd) linked through a specialized ADC linker, enabling targeted delivery of cytotoxic agents to cancer cells. It is utilized in research focused on the development of ADCs for improved therapeutic efficacy in oncology. -
Drug-Linker Conjugate for ADC
Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates a potent tubulin inhibitor, MMAE, with a stable linker (Mal-Val-Lys-PAB), enabling targeted delivery of chemotherapeutic agents. Mal-Val-Lys-PAB-MMAE is suitable for the synthesis of ADCs, facilitating research in cancer therapeutics and enhancing the efficacy of targeted therapies. -
Drug-Linker Conjugates for ADC
Aminooxy CatB-LXR is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It serves as a targeted delivery system that facilitates the coupling of therapeutic agents to antibodies, enhancing cytotoxicity specifically in cancer cells. This compound is instrumental in advancing research in ADC development, potentially improving therapeutic outcomes in oncology. -
Drug-Linker Conjugates for ADC
SDP-LIV1 drug-linker is a conjugate designed for antibody-drug conjugates (ADCs) that combines a potent topoisomerase I inhibitor with a specialized linker. This compound facilitates targeted drug delivery to cancer cells, enhancing the therapeutic efficacy of ADCs while minimizing systemic toxicity. SDP-LIV1 is suitable for research applications aimed at the development and optimization of ADC formulations in cancer therapeutics. -
Drug-Linker Conjugate for ADC
Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 functions as a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound integrates a potent NMT inhibitor with a stable and cleavable linker, facilitating targeted delivery of therapeutic agents. It is suitable for the synthesis and development of ADCs aimed at enhancing therapeutic efficacy in various cancer research applications. -
Drug-Linker Conjugates for ADC
m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. It combines a polyethylene glycol (PEG) spacer with a maleimide reactive group, allowing for efficient conjugation to antibodies, making it valuable for researchers developing novel ADCs for targeted cancer therapies. -
Drug-Linker Conjugates for ADC
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 serves as a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound integrates the ADC linker Mal-Phe-C4-VC-PAB with the potent cytotoxin DMEA-PNU-159682, which is derived from the metabolite profile of nemorubicin (MMDX) due to liver microsomal processing. Its primary biological activity involves targeted cytotoxicity to cancer cells, making it a valuable tool for research in cancer therapeutics and drug delivery systems. -
Drug-Linker Conjugates for ADC
Maytansine derivative M24 is a potent drug-linker conjugate targeting the development of antibody-drug conjugates (ADCs). It plays a crucial role in synthesizing ADCs, specifically REGN5093-M114, leveraging its mechanism of action for selective cytotoxicity in targeted cancer therapies. This compound is essential for researchers focused on enhancing therapeutic efficacy while minimizing off-target effects in oncology applications. -
Drug-Linker Conjugates for ADC
AMCC-DM1 is a drug-linker conjugate featuring the potent tubulin inhibitor DM4 and the non-cleavable linker AMCC. This compound is designed for use in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutic agents to cancer cells. Its unique structure allows for sustained cytotoxicity while minimizing off-target effects, making AMCC-DM1 a valuable tool for research in cancer therapeutics and ADC development. -
Drug-linker conjugate for ADC
APL-1091 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises the Mal-Exo-EEVC linker, which facilitates the attachment to antibodies, and MMAE, a potent microtubule inhibitor that disrupts cellular mitosis. This compound is essential for the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
Val-Cit-PAB-DEA-Dxd is a versatile drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound integrates a cleavable linker with the potent DNA topoisomerase I inhibitor Dxd, facilitating targeted delivery of the cytotoxic agent. Val-Cit-PAB-DEA-Dxd is suitable for synthesis of ADCs aimed at enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate for ADC
Tub114 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound is an analog of Tubulysin B, featuring a stable hydrophilic linker that enhances its suitability for the synthesis of ADCs. Tub114 exhibits key biological activity by selectively targeting and inhibiting tumor cell proliferation, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
PC6-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines the cytotoxic agent MMAE with a specialized linker, facilitating targeted delivery and enhanced therapeutic efficacy. PC6-VC-PAB-MMAE is suitable for the synthesis of ADCs, enabling focused research in cancer treatment and the development of innovative therapeutic strategies. -
Drug-Linker Conjugate for ADC
MC7 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This reagent features a payload that acts as a NAMPT inhibitor, facilitating targeted therapeutic delivery in cancer research. It is an essential tool for developing ADCs aimed at enhancing the efficacy of chemotherapy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-2 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), leveraging the potent antitumor activity of MMAE, a known tubulin polymerization inhibitor. The conjugate features a cleavable linker, MC-betaglucuronide, facilitating targeted delivery and release of the cytotoxic agent within tumor cells. This compound is suitable for research applications in oncology and cancer therapeutics, specifically in studies focused on ADC efficacy and mechanism of action. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Ala-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features the potent cytotoxic agent Exatecan linked through a flexible PEG8 spacer, enhancing its therapeutic efficacy. It is primarily utilized in the synthesis of ADCs to selectively deliver drugs to target cells, thereby improving the specificity and reducing off-target effects in cancer therapy research. -
Drug-Linker Conjugates for ADC
Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a mal-amido group linked to a PEG8 spacer and is optimized for efficient drug delivery and targeting. It enables the precise attachment of cytotoxic agents to antibodies, enhancing targeted therapeutic efficacy in cancer research and treatment development. -
Drug-Linker Conjugates for ADC
LE01 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It incorporates a linker suitable for ADC synthesis and the DNA topoisomerase I inhibitor DXd, facilitating targeted therapy. LE01 is particularly useful in generating HER2-targeting ADCs, enabling selective delivery of cytotoxic agents to HER2-expressing tumors for enhanced therapeutic efficacy. -
Drug-Linker Conjugates for ADC
Mal-VC-PAB-PNP-CDN-A is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. It employs a maleimide-based thiol-reactive mechanism to facilitate the site-specific attachment of cytotoxic drugs to monoclonal antibodies. This compound enhances the efficacy of ADCs by improving stability and targeted delivery, making it a valuable tool in cancer research and therapeutic development. -
Drug-linker conjugate for ADC
Fmoc-Gly-Gly-Phe-Gly-Docetaxel is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a microtubule depolymerization inhibitor, Docetaxel, linked through a peptide moiety, enabling targeted delivery of the cytotoxic agent to cancer cells. It is suitable for research applications focused on the development of ADC therapeutics for enhanced anti-cancer efficacy. -
Drug-Linker Conjugate for ADC
Mal-Toxophore is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. It features a payload that acts as a NAMPT inhibitor, contributing to targeted therapeutic efficacy. This compound is instrumental for researchers investigating ADC applications in cancer therapy and related fields, enabling the selective delivery of cytotoxic agents to cancer cells. -
Drug-Linker Conjugates for ADC
ST8154AA1 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that targets histone deacetylases (HDACs). This compound exhibits potent antitumor activity, making it a valuable tool for cancer research. Its application is particularly relevant in studies focused on developing targeted therapies and enhancing the efficacy of ADCs in oncology. -
Drug-Linker Conjugate For ADC
BrAc-Galactose-Sar-N-Me-alanine-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation with anti-TM4SF1 antibodies, enhancing targeted delivery of cytotoxic agents in cancer therapeutics. Its precise structural attributes enable efficient synthesis and potential for significant biological activity in research focused on ADC development and tumor targeting. -
Drug-Linker Conjugates for ADC
MMAE-PAB(p-glucuronide)-PEG3-aminooxy is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure allows for stable attachment to antibodies, making it suitable for research applications in cancer therapy and drug development. -
Drug-Linker Conjugates for ADC
CL2E-SN38 is a potent drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features SN-38, the active metabolite of Irinotecan, which acts as a Topoisomerase I inhibitor, disrupting DNA replication and transcription. Given its high release potential and structural stability, CL2E-SN38 is suitable for advanced cancer therapeutics research and the development of targeted treatments with reduced systemic toxicity. -
Drug-Linker Conjugates for ADC
G3-VC-PAB-DMEA-Duocarmycin DM is a duocarmycin-based drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs). This linker selectively releases the duocarmycin moiety upon internalization, leading to targeted cytotoxicity against cancer cells. Its applications include enhancing therapeutic efficacy in oncology research by selectively delivering cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates targeted delivery of cytotoxic agents to specific cells through selective binding to antibody moieties. It is useful in research focused on cancer therapeutics, enabling the study of immunoconjugate efficacy and safety profiles in various preclinical models. -
Drug-Linker Conjugate for ADC
Modified MMAF-C5-COOH is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It exhibits potent cytotoxic activity through the release of MMAF (monomethyl auristatin F), targeting and eliminating cancerous cells while minimizing damage to healthy tissues. This compound is essential for researchers developing ADC strategies for targeted cancer therapies.
